Tactile Systems Technology (TCMD) reported solid quarterly revenue growth driven by sales increases, offsetting a slight decline in rental revenue in Q1 2026. The company continues investing in sales, marketing, and R&D to expand its niche medical device offerings targeting lymphedema and airway clearance therapies. Its balance sheet remains strong with no debt and cash reserves exceeding $74 million, supporting ongoing share repurchases. While the business benefits from payer relationships and recurring rental streams, reimbursement and regulatory risks persist as watchpoints.